Ireland
--:--IST
Recruiting Not applicable

Efficacy of Dorso-lateral Prefrontal Cortex Stimulation by tDCS in Motor Conversion Disorder Patients

NCT04097184 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2021-03-05
Last updated
2025-02-13

Condition(s) studied

Conversion Disorder

Investigational drug(s) / intervention(s)

Neurostimulation with non-implanted electrodes

Neurostimulation with non-implanted electrodes: Neurostimulation with non-implanted electrodes

Study summary

Conversion disorder refers to impaired voluntary motor or sensory functions that are not compatible with a well-known neurological condition. This disorder affects up to 30% of hospitalized patients in neurology departments and symptoms persist in 35% of patients after 12 years of evolution. Despite a poor prognosis, no treatments have been validated to date.

The development of non-invasive brain stimulation techniques has allowed the creation of treatments focused on dysfunctional brain regions associated with motor conversion disorder. Hypoactivation of prefrontal dorso-lateral cortex underlies the course of functional motor symptoms. Results of the HYCORE study conducted at Nîmes University Hospital (including 20 patients, clinicaltrial.gov NCT02329626) confirmed these results and related hypoactivation of PFDLC to persistent motor disability at 3 months and 6 months follow-up. Activation of the PFDLC could restore executive control and thus promote the recovery of motor symptoms.

However, in most repeated Transcranial Magnetic Stimulation (rTMS) the primary motor areas were targeted and the clinical improvement was related to self-suggestion induced by the motor response produced.

Among the different techniques, transcranial Direct Current Stimulation (tDCS) is a medical neuromodulation device that delivers a direct, low-intensity electric current to cortical areas, facilitating neuronal activity. Recently, PFDLC stimulation via tDCS has been used to treat several neuropsychiatric disorders and shown to be effective in depression. In addition, this technique has several advantages compared to rTMS: its use is simpler and costs 5 to 8 times less, the device is portable and there is no titration procedure. The tolerance of the tDCS is also better with no risk of epileptic seizure, neuronal depolarization being absent.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * The patient must have given his/her informed and signed consent. * The patient is at least (≥) 18 years old and 65 years old at the most (≤). The risk of an increased frequency of somatic comorbidity, drug co-prescription, and cognitive impairment prompts us to limit recruitment to age 65 in this study. * The patient is hospitalized or followed in consultation. * Patient is available for a follow-up of 6 months. * With current DSM-5 criteria for conversion disorder during more than 10 days, motor type (i.e. with paralysis or motor weakness) and initial EDSS score ≥ 3 or initial WHO Score is ≥ 2 Exclusion Criteria: * The patient is participating in another interventional trial. * The patient refuses to sign the consent. * It is impossible to correctly inform the patient. * The patient is pregnant or breastfeeding. * Specialized neurological clinical examination and the performing of brain and medullary MRI reveal an organic neurological involvement. * Current episode of mania, hypomania, diagnosis of substance abuse/dependence (excluding smoking), diagnosis of schizophrenia over lifetime, severe neurological pathology (epilepsy, stroke, brain tumor). * Patient with a contraindication to MRI (for patients enrolled in Nîmes). * Acute eczema at the electrodes loci.

Primary outcome measure(s)

  • Evaluation of the efficacy of tDCS stimulation of the left PFDLC to treat motor disability in patients with conversion disorder 3 months after the intervention. — 3 months after the intervention
    Evaluation of the efficacy of tDCS stimulation of the left PFDLC to treat motor disability in patients with conversion disorder at 3 months after the stimulation procedure with the EDSS (Expanded Disability Status Scale). The Expanded Disability Status Scale is a rating scale of disability divided into eight systems or functional parameters, four major: pyramidal function, cerebellar function, sensory function and brainstem function; four minor: sphincters,vision, mind and others. An encrypted score of increasing severities (0 to 6 or 7) is given to each functional parameter. The overall score of the scale is measured on a scale of 20 levels (0 to 10 per half-point). Up to level 3.5, the score obtained in each functional parameter and the number of affected functional parameters automaticaly determines the EDSS score. From 4 to 7, the definition of each level is also given by the inability to walk (ability to walk without stopping - need for assistance).

Trial sites (8)

FacilityCityRegionStatus
Centre Hospitalier Universitaire Nîmes Gard Recruiting
Hôpital La Colombière Service de Psychiatrie Montpellier Hérault Not Yet Recruiting
CHU de Montpellier Hôpital Gui De Chauliac Service de Neurologie Montpellier Hérault Not Yet Recruiting
Hôpital Lapeyronie Montpellier Hérault Not Yet Recruiting
Hospices Civils de Lyon Hôpital Edouard Herriot Lyon France Not Yet Recruiting
CHU de Nantes Nantes France Not Yet Recruiting
Clinique St Exupery Toulouse France Not Yet Recruiting
Hôpital Saint-Antoine Service de Psychiatrie APHP Paris Île-de-France Region Not Yet Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04097184 on ClinicalTrials.gov ↗ ← All trials in France